3 recruiting, 1 completed. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 3, Completed 1 |
Follow CACAG+VEN: new trials by email Literature Review of CACAG+VEN trials Research Report on CACAG+VEN
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia CACAG+VEN, 3+7 - Acute Monocytic Leukemia | Phase 2 | Recruiting | Chinese PLA General Hospital | 204 | 2025-09-01 | 2026-04-06 |
| A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor, "3+7" - Acute Myeloid Leukemia, First Line Therapy | Phase 2 | Recruiting | Chinese PLA General Hospital | 160 | 2024-04-18 | 2026-05-08 |
| Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor, Best-Available Therapy(BAT) Regimen - Relapsed/Refractory Acute Myeloid Leukemia | Phase 2 | Recruiting | Chinese PLA General Hospital | 200 | 2023-08-01 | 2026-04-02 |
| Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor, "3+7" - Acute Myeloid Leukemia | Phase 2 | Completed | Chinese PLA General Hospital | 200 | 2023-03-01 | 2026-01-20 |
Leukemia, Myeloid, Acute (3) · Leukemia, Monocytic, Acute (1)
Chinese PLA General Hospital (4)
China (4)
Daihong Liu, doctor (2) · Liping Dou, Doctor (1)